CN115581696A - 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 - Google Patents

用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 Download PDF

Info

Publication number
CN115581696A
CN115581696A CN202211404315.3A CN202211404315A CN115581696A CN 115581696 A CN115581696 A CN 115581696A CN 202211404315 A CN202211404315 A CN 202211404315A CN 115581696 A CN115581696 A CN 115581696A
Authority
CN
China
Prior art keywords
xanomeline
trospium
pharmaceutical composition
oral pharmaceutical
beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211404315.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·贝坦库特
B·罗兰德
R·蒂伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of CN115581696A publication Critical patent/CN115581696A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202211404315.3A 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 Pending CN115581696A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862738333P 2018-09-28 2018-09-28
US62/738,333 2018-09-28
PCT/US2019/053429 WO2020069301A1 (en) 2018-09-28 2019-09-27 Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
CN201980064585.4A CN112789042A (zh) 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980064585.4A Division CN112789042A (zh) 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Publications (1)

Publication Number Publication Date
CN115581696A true CN115581696A (zh) 2023-01-10

Family

ID=69945518

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211404315.3A Pending CN115581696A (zh) 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
CN201980064585.4A Pending CN112789042A (zh) 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980064585.4A Pending CN112789042A (zh) 2018-09-28 2019-09-27 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Country Status (21)

Country Link
US (7) US10933020B2 (enExample)
EP (1) EP3856182B1 (enExample)
JP (4) JP7096441B2 (enExample)
KR (1) KR102408292B1 (enExample)
CN (2) CN115581696A (enExample)
AU (3) AU2019346626B2 (enExample)
BR (1) BR112021005802B1 (enExample)
CA (2) CA3114623C (enExample)
CL (2) CL2021000723A1 (enExample)
CO (1) CO2021005261A2 (enExample)
CR (1) CR20210212A (enExample)
EA (1) EA202190356A1 (enExample)
IL (3) IL295341B2 (enExample)
LT (1) LT3856182T (enExample)
MX (1) MX391629B (enExample)
NZ (1) NZ773719A (enExample)
PH (1) PH12021550616A1 (enExample)
SA (1) SA521421595B1 (enExample)
SG (1) SG11202102349PA (enExample)
UA (1) UA128017C2 (enExample)
WO (1) WO2020069301A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025167860A1 (zh) * 2024-02-06 2025-08-14 南京迈诺威医药科技有限公司 一种含有占诺美林或其盐的药物组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
MX391629B (es) 2018-09-28 2025-03-21 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico
CN120478350A (zh) * 2019-11-18 2025-08-15 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
JP2024507367A (ja) * 2021-02-24 2024-02-19 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための方法
US20220370454A1 (en) * 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
CN120535517A (zh) * 2022-06-14 2025-08-26 南京迈诺威医药科技有限公司 占诺美林的帕莫酸盐、晶型及其制备方法和用途
US12269818B2 (en) 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline
CN118267380B (zh) * 2024-05-31 2024-08-27 北京普诺旺康医药科技有限公司 呫诺美林-曲司氯铵缓释微球胶囊及其制备方法
WO2025255488A2 (en) 2024-06-06 2025-12-11 Karuna Therapeutics, Inc. Xanomeline quercetin complexes and trospium salts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011060A1 (en) * 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5480651A (en) 1992-03-16 1996-01-02 Regents Of The University Of California Composition and method for treating nicotine craving in smoking cessation
DE69430816T2 (de) * 1993-08-19 2002-12-19 Novo Nordisk A/S, Bagsvaerd Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
DE19612504C2 (de) 1996-03-29 2003-10-23 Boehringer Ingelheim Kg Neue Wirkstoffkompositionen
GB9612710D0 (en) 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
EP0821956A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821959A3 (en) 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
EP0821958A3 (en) 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
DK0821955T3 (da) 1996-08-01 2002-03-18 Lilly Co Eli Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
AU5716898A (en) 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
PL346247A1 (en) 1998-08-18 2002-01-28 Ucb Sa Muscarinic agonists and antagonists
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001268055A1 (en) 2000-06-30 2002-01-14 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
EP1352659A4 (en) 2000-12-22 2004-06-30 Takeda Chemical Industries Ltd COMBINATION DRUGS
EP1357900A2 (en) 2001-01-30 2003-11-05 Board of Regents, The University of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040023951A1 (en) 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
WO2003030818A2 (en) 2001-10-05 2003-04-17 Pichit Suvanprakorn Active agents using liposome beads
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US6887866B2 (en) * 2002-01-25 2005-05-03 Theravance, Inc. Short-acting sedative hypnotic agents for anesthesia and sedation
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
MXPA04010921A (es) 2002-05-03 2005-05-27 Israel Inst Biolog Res Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20050250767A1 (en) 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
GB0307860D0 (en) 2003-04-04 2003-05-14 Novartis Ag Organic compounds
WO2005044262A1 (en) * 2003-10-29 2005-05-19 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ES2359375T3 (es) 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR101157881B1 (ko) 2003-12-22 2012-07-06 아카디아 파마슈티칼스 인코포레이티드 무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CA2582385A1 (en) 2004-06-18 2005-12-18 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
GB0428170D0 (en) 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy
GB0428180D0 (en) 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy
US20060183733A1 (en) 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
JP4732769B2 (ja) 2005-03-04 2011-07-27 富士フイルム株式会社 内視鏡装置
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CN103142586A (zh) 2005-09-02 2013-06-12 塞拉维达公司 治疗疾病的疗法
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0607949D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2336275T3 (es) 2006-05-04 2010-04-09 Solvay Pharmaceuticals B.V. Agonistas muscarinicos para tratar trastornos del control de impulsos.
US7905852B2 (en) 2006-05-16 2011-03-15 Barbara Jennings-Spring Skin-contacting-adhesive free dressing
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US20100015184A1 (en) 2006-12-13 2010-01-21 Tuel Stephen M Methods of Making Pharmaceutical Components for Customized Drug Products
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
AU2008233232A1 (en) 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
WO2009036243A1 (en) 2007-09-12 2009-03-19 Glaxo Group Limited Novel combination of therapeutic agents
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
NO2200610T3 (enExample) 2007-09-21 2018-06-09
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
MX344177B (es) 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
US20110119259A1 (en) 2008-04-24 2011-05-19 Trustees Of Boston University Network biology approach for identifying targets for combination therapies
GB0822077D0 (en) 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
AU2010221133A1 (en) 2009-03-05 2011-09-22 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US10265311B2 (en) * 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2786716A1 (en) * 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US20120289529A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of trospium and salivary stimulants for the treatment of overactive bladder
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
US20130289019A1 (en) 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
CN104768540A (zh) 2012-09-05 2015-07-08 才思制药公司 抗胆碱能神经保护组合物和方法
EP3265067A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin-xanomeline transdermal therapeutic system combinations
US10307409B2 (en) * 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
US20180050018A1 (en) 2015-03-06 2018-02-22 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
JP6566254B2 (ja) 2015-08-21 2019-08-28 セイコープレシジョン株式会社 フォーカルプレーンシャッタおよび光学機器
HK1258048A1 (zh) 2015-09-01 2019-11-01 First Wave Bio, Inc. 用於治疗与异常炎症反应相关的病症的方法和组合物
EP3347012A4 (en) 2015-09-11 2019-04-17 Chase Pharmaceuticals Corporation MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM
CL2018000559A1 (es) 2015-10-14 2018-08-17 First Wave Bio Inc Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物
WO2017147104A1 (en) 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
MX391629B (es) 2018-09-28 2025-03-21 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico
US20210145804A1 (en) 2019-11-18 2021-05-20 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
CN120478350A (zh) 2019-11-18 2025-08-15 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
JP2024507367A (ja) 2021-02-24 2024-02-19 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための方法
US20220370454A1 (en) 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011060A1 (en) * 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴士良, 孙培红, 杨勇, 段继宏, 那彦群, 张小东, 丁强: "曲司氯铵治疗膀胱过度活动症的多中心临床研究", 中国新药杂志, no. 03, pages 96 - 98 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025167860A1 (zh) * 2024-02-06 2025-08-14 南京迈诺威医药科技有限公司 一种含有占诺美林或其盐的药物组合物

Also Published As

Publication number Publication date
CL2021003180A1 (es) 2022-09-30
JP7433351B2 (ja) 2024-02-19
AU2022224813B2 (en) 2024-09-05
EP3856182A4 (en) 2022-06-29
UA128017C2 (uk) 2024-03-13
IL295341B1 (en) 2024-09-01
CA3114623A1 (en) 2020-04-02
BR112021005802A2 (pt) 2021-06-29
LT3856182T (lt) 2026-01-26
PH12021550616A1 (en) 2021-10-04
IL295341B2 (en) 2025-01-01
US11890378B2 (en) 2024-02-06
JP2025118730A (ja) 2025-08-13
CA3180743A1 (en) 2020-04-02
AU2019346626B2 (en) 2022-06-02
US20240238205A1 (en) 2024-07-18
US10925832B2 (en) 2021-02-23
EP3856182B1 (en) 2025-12-24
JP2024026244A (ja) 2024-02-28
JP2022065045A (ja) 2022-04-26
IL281809A (en) 2021-05-31
KR20210062663A (ko) 2021-05-31
US20200101018A1 (en) 2020-04-02
US10933020B2 (en) 2021-03-02
NZ773719A (en) 2022-07-29
JP7096441B2 (ja) 2022-07-05
US11471413B2 (en) 2022-10-18
WO2020069301A1 (en) 2020-04-02
IL281809B (en) 2022-09-01
US20230181470A1 (en) 2023-06-15
EP3856182A1 (en) 2021-08-04
SG11202102349PA (en) 2021-04-29
US11452692B2 (en) 2022-09-27
US20220151933A1 (en) 2022-05-19
MX391629B (es) 2025-03-21
CN112789042A (zh) 2021-05-11
CR20210212A (es) 2021-09-24
IL314873A (en) 2024-10-01
EA202190356A1 (ru) 2021-08-13
US20200289419A1 (en) 2020-09-17
CL2021000723A1 (es) 2021-08-27
JP2021530572A (ja) 2021-11-11
AU2024267020A1 (en) 2025-01-02
IL295341A (en) 2022-10-01
JP7676512B2 (ja) 2025-05-14
CA3114623C (en) 2023-01-10
BR112021005802B1 (pt) 2022-02-15
KR102408292B1 (ko) 2022-06-10
US20210177762A1 (en) 2021-06-17
MX2021003621A (es) 2022-04-13
SA521421595B1 (ar) 2025-05-12
CO2021005261A2 (es) 2021-05-20
AU2022224813A1 (en) 2022-09-29
AU2019346626A1 (en) 2021-04-08
US20210154146A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7676512B2 (ja) ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
IL289974B (en) Methods and processes for non-invasive evaluation of genetic variations
CN115667235B (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
HK40126438A (zh) 用於治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
HK40044922A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
HK40125868A (zh) 用於治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
EA047978B1 (ru) Композиции и способы терапии заболеваний, ослабленных активацией мускариновых рецепторов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230110

WD01 Invention patent application deemed withdrawn after publication